Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Olesen, Uffe H ^a,b   Petersen, Jakob G ^a,b   Garten, Antje ^c   Kiess, Wieland ^c   Yoshino, Jun ^d   Imai, Shin Ichiro ^d   Christensen, Mette K ^b   Fristrup, Peter ^e   Thougaard, Annemette V ^b   Björkling, Fredrik ^b,f   Jensen, Peter B ^b   Nielsen, Søren J ^b   Sehested, Maxwell ^a,b  

^a University of Copenhagen   (Denmark)

^b BioAlliance Pharma   (France)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DAPORINAD; MESSENGER RNA; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SEPHAROSE; TP 201565; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; CYANIDE; CYTOKINE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; N (4 (1 BENZOYLPIPERIDIN 4 YL)BUTYL) 3 (PYRIDIN 3 YL)ACRYLAMIDE; N (6 CHLOROPHENOXYHEXYL) N'' CYANO N'' 4 PYRIDYLGUANIDINE; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; N-(6-CHLOROPHENOXYHEXYL)-N''-CYANO-N''-4-PYRIDYLGUANIDINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL LYSATE; CELL STRAIN HCT116; CELL STRAIN HEK293; CELL STRAIN HEPG2; COMPETITIVE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRECIPITATION; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; BINDING COMPETITION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; IC 50; METABOLISM; MUTATION; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROTEIN CONFORMATION; TIME; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CELL LINE, TUMOR; CYANIDES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GUANIDINES; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MODELS, MOLECULAR; MUTATION; NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; PROTEIN CONFORMATION; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649947146     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-677     Document Type: Article

References (45)

1. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009, 8(9):709-723. 10.1038/nrd2871, 19629074.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531):876-880. 10.1126/science.1062538, 11423618.
3. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002, 9(4):303-307. 10.1097/00062752-200207000-00007, 12042704.
4. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006, 16(1):92-99. 10.1016/j.gde.2005.11.002, 16343892.
5. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 2000, 267(6):1550-1564. 10.1046/j.1432-1327.2000.01187.x, 10712584.
6. Diefenbach J, Burkle A. Introduction to poly(ADP-ribose) metabolism. Cell Mol Life Sci 2005, 62(7-8):721-730. 10.1007/s00018-004-4503-3, 15868397.
7. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007, 26(37):5489-5504. 10.1038/sj.onc.1210616, 17694089.
8. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13(6):472-482. 10.1016/j.ccr.2008.05.005, 18538731.
9. Hageman GJ, Stierum RH. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res 2001, 475(1-2):45-56.
10. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396(6712):643-649. 10.1038/25292, 9872311.
11. Nomura F, Yaguchi M, Togawa A, Miyazaki M, Isobe K, Miyake M, Noda M, Nakai T. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol 2000, 15(5):529-535. 10.1046/j.1440-1746.2000.02193.x, 10847440.
12. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004, 279(49):50754-50763. 10.1074/jbc.M408388200, 15381699.
13. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007, 23(2):164-170. 10.1097/MOG.0b013e32801b3c8f, 17268245.
14. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 2006, 13(7):582-588. 10.1038/nsmb1105, 16783377.
15. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, Kang GB, Lee YS, Kim JB, Kim KK, Suh SW, et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol 2006, 362(1):66-77. 10.1016/j.jmb.2006.06.082, 16901503.
16. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 2006, 13(7):661-662. 10.1038/nsmb1114, 16783373.
17. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003, 63(21):7436-7442.
18. Clark JB, Ferris GM, Pinder S. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide. Biochim Biophys Acta 1971, 238(1):82-85.
19. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 2003, 278(51):50985-50998. 10.1074/jbc.M306552200, 14522996.
20. Sauve AA, Schramm VL. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 2003, 42(31):9249-9256. 10.1021/bi034959l, 12899610.
21. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjornelund J, Dawson KM, Dupuis M, Duchosal MA. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009, 113(14):3276-3286. 10.1182/blood-2008-08-173369, 19196867.
22. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008, 26(1):45-51. 10.1007/s10637-007-9083-2, 17924057.
23. Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999, 59(22):5751-5757.
24. Olesen UH, Christensen MK, Bjorkling F, Jaattela M, Jensen PB, Sehested M, Nielsen SJ. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008, 367(4):799-804. 10.1016/j.bbrc.2008.01.019, 18201551.
25. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lonnebo A, Ahlgren J. A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 2002, 8(9):2843-2850.
26. Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005, 41(5):702-707. 10.1016/j.ejca.2004.12.023, 15763645.
27. Pishvaian M, Marshall J, Hwang J, Malik S, He A, Deeken J, Kelso C, Cotaria I, Berger M. A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. 2009 ASCO Annual Meeting: 2009: ASCO 2009,
28. Schou C, Ottosen ER, Petersen HJ, Björkling F, Latini S, Hjarnaa PV, Bramm E, Binderup L. Novel cyanoguanidines with potent oral antitumour activity. Bioorg Med Chem Lett 1997, 7(24):3095-3100.
29. Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindelov L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 1993, 67(2):311-320. 1968190, 8094293.
30. Olesen UH, Thougaard AV, Jensen PB, Sehested M. A preclinical study on the rescue of normal tissue by nicotinic acid in high dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 2010, 9(6):1609-1617. 10.1158/1535-7163.MCT-09-1130, 20515945.
31. Elliott GC, Ajioka J, Okada CY. A rapid procedure for assaying nicotinamide phosphoribosyltransferase. Anal Biochem 1980, 107(1):199-205. 10.1016/0003-2697(80)90512-6, 6449162.
32. Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, Kratzsch J, Kiess W, Gebhardt R. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2009, 391(1):376-381. 10.1016/j.bbrc.2009.11.066, 19912992.
33. Mattos C. Protein-water interactions in a dynamic world. Trends Biochem Sci 2002, 27(4):203-208. 10.1016/S0968-0004(02)02067-4, 11943548.
34. Gullbo J, Lovborg H, Dhar S, Lukinius A, Oberg F, Nilsson K, Bjorkling F, Binderup L, Nygren P, Larsson R. Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anticancer Drugs 2004, 15(1):45-54. 10.1097/00001813-200401000-00008, 15090743.
35. Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, Bernier C, Branchaud S, Chan H, Dairi K, et al. The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors. Mol Cell Biol 2009, 29(21):5872-5888. 10.1128/MCB.00112-09, 2772749, 19703994.
36. Hassan SB, Jonsson E, Larsson R, Karlsson MO. Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J Pharmacol Exp Ther 2001, 299(3):1140-1147.
37. Martinsson P, de la Torre M, Binderup L, Nygren P, Larsson R. Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol 2001, 417(3):181-187. 10.1016/S0014-2999(01)00925-6, 11334849.
38. Olsen LS, Hjarnaa PJ, Latini S, Holm PK, Larsson R, Bramm E, Binderup L, Madsen MW. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer 2004, 111(2):198-205. 10.1002/ijc.20255, 15197771.
39. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6(5):363-375. 10.1016/j.cmet.2007.09.003, 2098698, 17983582.
40. Hovstadius P, Lindhagen E, Hassan S, Nilsson K, Jernberg-Wiklund H, Nygren P, Binderup L, Larsson R. Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs 2004, 15(1):63-70. 10.1097/00001813-200401000-00010, 15090745.
41. Formentini A, Henne-Bruns D, Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 2004, 389(5):405-413. 10.1007/s00423-004-0510-y, 15309542.
42. Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother 2004, 16(Suppl 4):25-30.
43. Khan JA, Forouhar F, Tao X, Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 2007, 11(5):695-705. 10.1517/14728222.11.5.695, 17465726.
44. Galli U, Ercolano E, Carraro L, Blasi Roman CR, Sorba G, Canonico PL, Genazzani AA, Tron GC, Billington RA. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem 2008, 3(5):771-779. 10.1002/cmdc.200700311, 18247435.
45. Kang GB, Bae MH, Kim MK, Im I, Kim YC, Eom SH. Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. Mol Cells 2009, 27(6):667-671. 10.1007/s10059-009-0088-x, 19533035.